Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 4, 2020

Primary Completion Date

November 11, 2020

Study Completion Date

June 21, 2021

Conditions
Sars-CoV-2Covid19
Interventions
DRUG

BLD-2660

BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9.

Trial Locations (35)

13034

Blade Research Site, Campinas

15090

Blade Research Site, São José do Rio Preto

18618

Blade Research Site, Botucatu

19140

Blade Research Site, Philadelphia

20007

Blade Research Site, Washington D.C.

20010

Blade Research Site, Washington D.C.

21201

Blade Research Site, Baltimore

27708

Blade Research Site, Durham

28304

Blade Research Site, Fayetteville

29041

Blade Research Site, Vitória

29414

Blade Research Site, Charleston

Blade Research Site, Charleston

30150

Blade Research Site, Belo Horizonte

32405

Blade Research Site, Panama City

33511

Blade Research Site, Brandon

33620

Blade Research Site, Tampa

34982

Blade Research Site, Ft. Pierce

37203

Vanderbilt University Medical Center, Nashville

40207

Blade Research Site, Louisville

40503

Blade Research Site, Lexington

41810

Blade Research Site, Bahia

48202

Blade Research Site, Detroit

48334

Blade Research Site, Farmington Hills

50010

Blade Research Site, Ames

61603

Blade Research Site, Peoria

65470

Blade Research Site, Ribeirão Preto

68114

Blade Research Site, Omaha

75203

Blade Research Site, Dallas

76801

Blade Research Site, Porto Velho

83404

Blade Research Site, Idaho Falls

90048

Blade Research Site, Los Angeles

92697

Blade Research Site, Irvine

95128

Blade Reseach Site, San Jose

99204

Blade Research Site, Spokane

07450

Blade Research Site, Ridgewood

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Clinipace Worldwide

INDUSTRY

lead

Blade Therapeutics

INDUSTRY